1637773-61-5

Basic information

• Product Name: 4-(2-cyclopropyl-4-iodo-1H-benzo [d]imidazol-6-yl)-3,5-dimethylisoxazole
• CAS NO: 1637773-61-5
• Molecular Weight: 379.2
• Mol File: 1637773-61-5.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 4-(2-cyclopropyl-4-iodo-1H-benzo [d]imidazol-6-yl)-3,5-dimethylisoxazole(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-cyclopropyl-4-iodo-1H-benzo [d]imidazol-6-yl)-3,5-dimethylisoxazole(1637773-61-5)
• EPA Substance Registry System: 4-(2-cyclopropyl-4-iodo-1H-benzo [d]imidazol-6-yl)-3,5-dimethylisoxazole(1637773-61-5)

Safety Data

• Hazardous Substances Data: 1637773-61-5(Hazardous Substances Data)

Usage

Chemical compound

4-(2-cyclopropyl-4-iodo-1H-benzo [d]imidazol-6-yl)-3,5-dimethylisoxazole
Isoxazole derivative with a cyclopropyl and an iodine group attached to a benzimidazole ring
Contains two methyl groups attached to the isoxazole ring
Potential biological activity due to its structural features
Applications in medicinal chemistry and drug discovery
Potential for development of new pharmaceutical agents with therapeutic effects
Further research needed to determine full range of biological activities and potential uses.

Upstream product

• 832114-00-8 3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole 
• 1629614-02-3 5-(3,5-dimethylisoxazol-4-yl)-3-iodobenzene-1,2-diamine 
• 4023-34-1 cyclopropanecarboxylic acid chloride 
• 875-51-4 4-Bromo-2-nitroaniline 

Downstream Products

• 1637770-13-8 4-(2-cyclopropyl-7-(6-methylquinolin-5-yl)-1H-benzo[d]imidazol-5-yl)-3,5-dimethylisoxazole 

Relevant articles and documents

Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor

The bromodomain and extra-terminal (BET) family of proteins, consisting of the bromodomains containing protein 2 (BRD2), BRD3, BRD4, and the testis-specific BRDT, are key epigenetic regulators of gene transcription and has emerged as an attractive target for anticancer therapy. Herein, we describe the discovery of a novel potent BET bromodomain inhibitor, using a systematic structure-based approach focused on improving potency, metabolic stability, and permeability. The optimized dimethylisoxazole aryl-benzimidazole inhibitor exhibited high potency towards BRD4 and related BET proteins in biochemical and cell-based assays and inhibited tumor growth in two proof-of-concept preclinical animal models.